HASBROUCK HEIGHTS, NJ (August 9, 2017) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is
pleased to announce recent completion of private placements with proceeds totaling US $3.0 million. There
were no warrants or fees associated with the transactions. The placements were with long-term
shareholders of the Company, and will be used for general corporate purposes.
The Company announced on August 7 that an important large symposium and panel discussion of the
Company’s new drug Fexapotide Triflutate will be held at the September meeting of the American
Urological Association, Mid-Atlantic Section. The September symposium at the AUA meeting will feature
presentations from prominent Fexapotide Clinical Trial urologists, and will include panel discussions of data
and results from the U.S. Fexapotide trials undertaken in 2009-2017. The Chairperson of the Symposium
will be Ronald Tutrone MD, FACS of Chesapeake Urology, Towson, MD.
Categorised in: Upcoming Events
This post was written by nymadm